新冠疫情期间丹麦儿童青少年及年轻成人精神药物使用与精神障碍诊断变化
这项基于丹麦全国登记数据的描述性队列研究纳入2017年1月至2022年6月所有5至24岁个体,比较疫情开始后观察到的精神药物新使用与精神障碍新诊断数量与基于疫情前趋势预测的预期数量。结果显示,2020年3月至2022年6月期间,任何精神药物新使用率相对增加18%(RR 1.18;CI 1.17-1.20),12至17岁组增加37%(RR 1.37;95%CI 1.34-1.41);精神障碍新诊断率相对增加5%(IR 1.05;CI 1.04-1.07),主要与多动性障碍(RR 1.13;CI 1.09-1.18)和焦虑障碍(RR 1.04;CI 1.02-1.06)增加相关。
要点
- 疫情期间丹麦5-24岁人群精神药物新使用率较预期增加18%,12-17岁组增加37%。
- 精神障碍新诊断率较预期增加5%,多动性障碍和焦虑障碍诊断增加。
- 无论近5年有无精神病史,儿童青少年中均观察到上述增加。
核心结论
- 丹麦5至24岁人群在新冠疫情期间精神药物使用率和精神障碍诊断率均较疫情前趋势预测值上升,以12至17岁青少年最为明显。
研究设计与样本
- 基于丹麦全国登记数据的 population-based 描述性队列研究,纳入2017年1月1日至2022年6月30日所有5至24岁丹麦个体。
主要发现
- 2020年3月至2022年6月,任何精神药物新使用率较预期相对增加18%(RR 1.18;CI 1.17-1.20),12至17岁组增加37%(RR 1.37;95%CI 1.34-1.41)。
- 患病率趋势显示精神药物使用和精神障碍总体增加的模式相似。
- 某一药物组的新使用者中,有1/3在之前6个月内曾配取另一精神药物组的处方。
临床怎么用
- 临床应关注疫情期间及之后儿童青少年精神药物使用和精神障碍诊断需求的增加,尤其是12至17岁人群。
- 对于新启用某一类精神药物的青少年,需注意其近6个月内可能已使用其他类别精神药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The direct and indirect implications of the COVID-19 pandemic have been associated with the mental health of children and adolescents, but it is uncertain whether these implications have been associated with changes in prescribing and diagnosis patterns. OBJECTIVE: To examine psychotropic medication use and rates of psychiatric disorders in Danish children, adolescents, and young adults during the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: This population-based, descriptive register-based cohort study included all Danish individuals aged 5 to 24 years from January 1, 2017, until June 30, 2022. MAIN OUTCOMES AND MEASURES: Rates of filled prescriptions of psychotropic medications, including antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants, and psychostimulants, and all inpatient and outpatient contacts with mental and behavioral disorders. Rates of new (incident) and total (prevalent) psychotropic medication use and psychiatric diagnoses were estimated. Rate ratios (RRs) were assessed between observed and expected numbers of incident psychotropic medication use or psychiatric diagnoses from March 2020 to June 30, 2022, comparing observed numbers with expected numbers predicted from the modeled prepandemic trend. RESULTS: The study identified 108 840 (58 856 female individuals [54%]; median [IQR] age, 18 [14-22] years) incident psychotropic medication users. From March 2020 (first national lockdown) to June 2022, the rate of incident users of any psychotropic medication showed a relative increase of 18% (RR, 1.18; CI, 1.17-1.20) compared with expected numbers, which was primarily associated with an increase among those aged 12 to 17 years of 37% (RR, 1.37; 95% CI, 1.34-1.41). Similarly, there was an overall relative increase of incident psychiatric disorders of 5% (incidence rate, 1.05; CI, 1.04-1.07) (incident cases, 114 048 [58 708 female individuals (51%)]), which was associated with an increase in hyperkinetic disorders (RR, 1.13; CI, 1.09-1.18) and anxiety disorders (RR, 1.04; CI, 1.02-1.06). Prevalence patterns showed similar trends of an overall increase in psychotropic medication use and psychiatric disorders. One of 3 new users of an individual drug group had filled a prescription for a drug from another psychotropic medication group within the prior 6 months. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that Danish youths experienced an increase in rates of psychotropic treatment and psychiatric disorder diagnoses during the COVID-19 pandemic, which was most pronounced among those aged 12 to 17 years. The increase was observed for children and adolescents with and without a psychiatric history within the last 5 years.
引用
- Bliddal M, Rasmussen L, Andersen JH, et al. Psychotropic Medication Use and Psychiatric Disorders During the COVID-19 Pandemic Among Danish Children, Adolescents, and Young Adults. JAMA Psychiatry. 2023. PMID: 36515919. doi:10.1001/jamapsychiatry.2022.4165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。